Docoh
Loading...

HZNP Horizon Therapeutics

News

From Benzinga Pro
Horizon Therapeutics Topline Results Met Primary Endpoint For KRYSTEXXA With Methotrexate
25 Oct 21
Biotech, News, FDA, General
-- Horizon expects to file a Supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration in first quarter of 2022 based on significant improvement in response rate -- --
Horizon Therapeutics Highlights Newly-Published Data On Long-Term Efficacy For Co.'s TEPEZZA For Thyroid Eye Disease In 'Ophthalmology'
21 Oct 21
Biotech, News, FDA, General
-- Comprehensive OPTIC-X trial results published in Ophthalmology, including new long-term follow-up data -- DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (NASDAQ:HZNP) today announced additional data supporting
Horizon Therapeutics Reports Results From New Analysis Of UPLIZNA Phase 2/3 Trial Showing A Correlation Between Depth Of B-Cell Depletion, Improved Neuromyelitis Optica Spectrum Disorder Patient Outcomes
13 Oct 21
Biotech, News, FDA, General
-- Findings presented at ECTRIMS 2021 suggest that deep, persistent B-cell depletion is linked to reduced disease activity -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced results from a new analysis of the
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
5 Oct 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4)
Horizon Therapeutics plc Announces New UPLIZNA Data In Neuromyelitis Optica Spectrum Disorder To Be Presented At ECTRIMS 2021
4 Oct 21
Biotech, General
Horizon Therapeutics plc (NASDAQ:HZNP) today announced that new UPLIZNA and NMOSD data analyses will be presented at the virtual 37th Congress of the European Committee for Treatment and Research in Multiple
SEC Charges Former Goldman Sachs Officer For Insider Trading On 2 M&A Deals
1 Oct 21
Biotech, M&A, News, Health Care, Legal, General
Horizon Therapeutics Highlights Data Showing UPLIZNA Also Produces B-Cell Depletion In African Americans With Neuromeylitis Optica Spectrum Disorder
23 Sep 21
Biotech, News, FDA, General
-- Analysis of 20 African Americans from the pivotal study presented at the 15th World Congress on Controversies in Neurology -- DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (NASDAQ:HZNP) today announced results
9 Health Care Stocks Showing Unusual Options Activity In Today's Session
21 Sep 21
Options
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. Unusual trading activity could push option prices to exaggerated or underestimated levels.
Morgan Stanley Maintains Overweight on Horizon Therapeutics, Raises Price Target to $135
26 Aug 21
News, Price Target, Analyst Ratings
Morgan Stanley analyst Michael Ulz maintains Horizon Therapeutics (NASDAQ:HZNP) with a Overweight and raises the price target from $103 to $135.
Goldman Sachs Maintains Neutral on Horizon Therapeutics, Raises Price Target to $107
24 Aug 21
News, Price Target, Analyst Ratings
Goldman Sachs maintains Horizon Therapeutics (NASDAQ:HZNP) with a Neutral and raises the price target from $96 to $107.
9 Health Care Stocks With Unusual Options Alerts In Today's Session
23 Aug 21
Options
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. Unusual trading activity could push option prices to exaggerated or underestimated levels.
Analyzing Horizon Therapeutics's Unusual Options Activity
11 Aug 21
Movers
On Wednesday, shares of Horizon Therapeutics (NASDAQ:HZNP) saw unusual options activity. After the option alert, the stock price moved down to $104.69.
Understanding Horizon Therapeutics's Unusual Options Activity
10 Aug 21
Movers
On Tuesday, shares of Horizon Therapeutics (NASDAQ:HZNP) saw unusual options activity. After the option alert, the stock price moved down to $104.39.
Citigroup Maintains Buy on Horizon Therapeutics, Raises Price Target to $121
5 Aug 21
News, Price Target, Analyst Ratings
Citigroup analyst Navann Ty maintains Horizon Therapeutics (NASDAQ:HZNP) with a Buy and raises the price target from $117 to $121.
BMO Capital Maintains Outperform on Horizon Therapeutics, Raises Price Target to $132
5 Aug 21
News, Price Target, Analyst Ratings
BMO Capital analyst Gary Nachman maintains Horizon Therapeutics (NASDAQ:HZNP) with a Outperform and raises the price target from $118 to $132.
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
5 Aug 21
Biotech, Earnings, News, Penny Stocks, Guidance, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4)
Analyzing Horizon Therapeutics's Unusual Options Activity
4 Aug 21
Movers
Horizon Therapeutics (NASDAQ:HZNP) shares experienced unusual options activity on Wednesday. The stock price moved up to $108.74 following the option alert.
Horizon Therapeutics Stock Shoots Higher As Relaunch Of Thyroid Eye Disease Med Boosts Q2 Sales; Raises FY21 Outlook
4 Aug 21
Biotech, Earnings, Long Ideas, News, Guidance, Health Care, Movers, Trading Ideas, General
Horizon Therapeutics Earlier Reported Q2 EPS $1.62 Beats $0.88 Estimate, Sales $832.55M Beat $685.03M Estimate
4 Aug 21
Earnings, News
Horizon Therapeutics (NASDAQ:HZNP) reported quarterly earnings of $1.62 per share which beat the analyst consensus estimate of $0.88 by 84.09 percent. This is a 305 percent increase over earnings of $0.40 per share from
Stocks That Hit 52-Week Highs On Wednesday
4 Aug 21
News, Intraday Update, Markets, Movers, Trading Ideas
Before 10 a.m. ET Wednesday, 138 stocks hit new 52-week highs.

Press releases

From Benzinga Pro
Horizon Therapeutics plc Named to Newsweek's List of the Most Loved Workplaces for 2021
22 Oct 21
Press Releases
Horizon Therapeutics plc (NASDAQ:HZNP) today announced that is has been named to Newsweek's inaugural Most Loved Workplaces list for 2021, ranking among the top 100 companies recognized for employee happiness and
Newly Published Data Continue to Support Long-Term Efficacy of TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)
21 Oct 21
Press Releases
-- Comprehensive OPTIC-X trial results published in Ophthalmology, including new long-term follow-up data -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced additional data supporting the long-term efficacy of
Horizon Therapeutics plc to Release Third-Quarter 2021 Financial Results and Host Webcast on Nov. 3, 2021
11 Oct 21
Press Releases
Horizon Therapeutics plc (NASDAQ:HZNP) announced today that its third-quarter 2021 financial results will be released on Wednesday, Nov. 3, 2021. Following the announcement, Horizon's management will host a live
New Analysis Published in Multiple Sclerosis Journal Assesses Long-Term Use of UPLIZNA® (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
4 Oct 21
Press Releases
-- Data show notable decline in disease-related attacks after the first year of treatment in patients receiving UPLIZNA for four or more years -- -- Consistent safety profile maintained throughout long-term study
Horizon Therapeutics plc Announces New Development Programs at Virtual R&D Day
29 Sep 21
Press Releases
-- Announcing Five Total New Development Programs for Daxdilimab (HZN-7734) and Dazodalibep (HZN-4920); Expect to Initiate New Phase 2 Trials in 2022, Bringing Total Development Programs to 27 -- --Positioned for
Horizon Therapeutics plc Announces Agenda for Virtual R&D Day for Investors and Analysts on Sept. 29, 2021
23 Sep 21
Press Releases
-- Event Begins at 9 a.m. ET -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced the agenda for its virtual R&D Day for investors and analysts on Sept. 29, 2021. During the event, Horizon's R&D
Horizon Therapeutics plc Announces Data Showing UPLIZNA® (inebilizumab-cdon) Also Produces Rapid and Sustained B-Cell Depletion in African Americans with Neuromyelitis Optica Spectrum Disorder (NMOSD)
23 Sep 21
Press Releases
-- Analysis of 20 African Americans from the pivotal study presented at the 15th World Congress on Controversies in Neurology -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced results of a retrospective
HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline
21 Sep 21
News, Contracts, Press Releases
CHARLOTTESVILLE, Va., Sept. 21, 2021 /PRNewswire/ -- HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product
Horizon Therapeutics plc Named One of the 2021 Best Workplaces for Women™ by Fortune and Great Place to Work®
16 Sep 21
Press Releases
Horizon Therapeutics plc (NASDAQ:HZNP) today announced that it has been named to the 2021 Best Workplaces for Women™ list for the first time by Fortune and Great Place to Work®. The Best Workplaces for Women
Horizon Therapeutics plc Initiates Randomized Controlled Clinical Trial Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Chronic (Inactive) Thyroid Eye Disease (TED)
7 Sep 21
Press Releases
Horizon Therapeutics plc (NASDAQ:HZNP) today announced that the first patient has been enrolled in a Phase 4 clinical trial evaluating the efficacy and safety of TEPEZZA for the treatment of chronic (inactive) TED.
Horizon Therapeutics plc Named One of PEOPLE's 100 Companies That Care®
1 Sep 21
Press Releases
Horizon Therapeutics plc (NASDAQ:HZNP) today announced that it has been named to PEOPLE's 100 Companies That Care® 2021 list for the third year by PEOPLE and Great Place to Work®. The PEOPLE Companies that
Horizon Therapeutics plc to Participate in Upcoming Conferences
23 Aug 21
Press Releases
Horizon Therapeutics plc (NASDAQ:HZNP) today announced that the Company will participate in the following conferences: Handelsbanken Life Science Innovation Day 2021 (Virtual) Date: Wednesday, Aug. 25,
Thinking about trading options or stock in Horizon Therapeutics, MGM Resorts, RingCentral, Apple, or NVIDIA?
4 Aug 21
Opinion, Press Releases
NEW YORK, Aug. 4, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HZNP, MGM, RNG, AAPL, and NVDA.